Pre-ASRM prep notes, part 2.

Back in 2015 I wrote a piece for Forbes that made a bunch of predictions about where IVF was heading. Time to re-examine. (The original article is online: [https://www.forbes.com/sites/davidsable/2015/02/28/the-seven-trends-that-define-the-future-of-ivf/?sh=5c2a12cf494b])

Then:
Prediction 1. IVF for the prevention of disease: The combination of 1) inexpensive human genome sequencing…


Part 1: artificial intelligence in IVF, private equity, the unexpected legacy of Covid-19 on IVF practice and the minefield of “add-on” pricing

Regarding AI in IVF, the good news for the IVF world is that the people developing artificial intelligence for IVF are outstanding: visionary, knowledgable about data, science, patient…


Time for the US HHS to take a lesson from early stage venture capitalists re accelerated approval.

Recent case: drug found to have proof of concept but not of benefit (ie does not pass the “so what” test — yet.) …


I’ve become a regular listener of Griffin Jones’ podcast “Inside Reproductive Health,” and his episode this week is particularly enlightening. He had on Brian Levine, a founding RE at CCRM in New York.

I initially met Brian a couple of years ago, and found him to be an admirably entrepreneurial…


I spent some time with the excellent Women’s Health Investment piece by @chrissyfarr et al (https://ovsecondopinion.substack.com/p/why-were-betting-big-on-womens-health). At the risk of mansplaining women’s health, some observations, with an Ob/Gyn/reproductive endocrinologist bias:

The article is spot on that women’s health is only now emerging from healthcare’s analog past — what I leaned…


My Columbia Classroom Is Not A Safe Place

Originally published in Forbes, Dec 11, 2015

Today is the last day of class for BIOT 4180, Entrepreneurship in Biotechnology. This semester was a bit of a departure from past versions of the course. Instead of the 400+ students I lectured to…


Working on an IVF investment thesis and wanted yet another data point to support the size of the as-yet unmet market. This question is usually approached (appropriately) by patient metrics: infertility prevalence, recurrent preg loss, oncofertility, LGBTQ eg. Wanting to add another layer to the data, I looked for policy…


(originally appeared in Forbes, Mar 7, 2014, titled “Hedging Strategies in a Hot Biotech Market (part 2)”)

The Wall Street Journal reported this morning that the Allman Brothers are ending their yearly March concert series at the Beacon Theater in my Upper West Side neighborhood. …


What does precision medicine mean for biotechnology? It means a future where every inherited genetic disease is curable.

What does precision medicine mean for assisted reproduction? It means a present where these same diseases are preventable. …


The Columbia Business School Alumni Association packed a midtown conference room last week to discuss the Business of Reproductive Medicine. …

David Sable

bio fund manager, Columbia prof, ex-reproductive endocrinologist, roadie for @PriyaMayadas

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store